Pharmacology of CS-747 (prasugrel, LY640315), a Novel, Potent Antiplatelet Agent with in Vivo P2Y<sub>12</sub>Receptor Antagonist ActivityY. Niitsu, Fumitoshi Asai, Joseph A. Jakubowski et al.|Seminars in Thrombosis and Hemostasis|2005Cited by 236
The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel’s active metaboliteAtsuhiro Sugidachi, Fumitoshi Asai, Taketoshi Ogawa et al.|Journal of Thrombosis and Haemostasis|2007Cited by 220
A multiple dose study of prasugrel (CS‐747), a novel thienopyridine P2Y<sub>12</sub> inhibitor, compared with clopidogrel in healthy humansJoseph A. Jakubowski, Kenneth J. Winters, Nobuko Matsushima et al.|British Journal of Clinical Pharmacology|2006Cited by 128
Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y<sub>12</sub> inhibitor: A single ascending dose study in healthy humansFumitoshi Asai, Kenneth J. Winters, Joseph A. Jakubowski et al.|Platelets|2006Cited by 108
Interaction of the active metabolite of prasugrel, R-138727, with cysteine 97 and cysteine 175 of the human P2Y12 receptorIrina Algaier, Ivar von Kügelgen, Joseph A. Jakubowski et al.|Journal of Thrombosis and Haemostasis|2008Cited by 94